Latest Quest Diagnostics Inc (DGX) Headlines Co
Post# of 63
Posted On: 03/14/2014 1:36:12 PM
Latest Quest Diagnostics Inc (DGX) Headlines
Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest Diagnostics, and Illumina
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Medtronic, Inc. (NYSE: MDT), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and Illumina, Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Quest Diagnostics to Buy Summit Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:00PM CDT
Post acquisition, Summit Health's services will complement the health and wellness business of Quest Diagnostics.
Fitch Downgrades Quest Diagnostics' IDR to 'BBB'; Outlook Stable
Business Wire - Wed Mar 12, 9:31AM CDT
Fitch Ratings has downgraded Quest Diagnostics, Inc.'s (Quest) ratings as follows and removed the ratings from Rating Watch Negative:
Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
PR Newswire - Wed Mar 12, 8:24AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $600,000,000 in aggregate principal amount of two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.
After Yesterday's Rally of 2.79% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 11, 5:35PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $53.07 to a high of $54.50. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $53.02 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Quest Diagnostics to Potentially Pullback After Gaining 2.79% Yesterday
Comtex SmarTrend(R) - Tue Mar 11, 5:34PM CDT
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $53.07 to a high of $54.50. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $53.02 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Quest Diagnostics Ups View on Solstas Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 4:20PM CDT
With the declaration of the closure of its earlier announced acquisition of Solstas Lab Partners Group and its subsidiaries, Quest Diagnostics also raised its 2014 financial outlook.
Clifford Chance advising Summit Health on its sale to Quest Diagnostics
GlobeNewswire - Tue Mar 11, 4:18PM CDT
Clifford Chance is advising Summit Health, a leading provider of on-site prevention and wellness programs primarily for employers, on its sale to Quest Diagnostics, the world's leading provider of diagnostic information services. The deal is subject to regulatory approvals and other customary closing conditions, and is expected to close in the first half of 2014. Terms of the transaction were not disclosed.
Myriad Stock Tumbles After Court Allows Rival To Sell
at Investor's Business Daily - Tue Mar 11, 10:18AM CDT
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for...
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Quest Diagnostics to Acquire Summit Health
PR Newswire - Tue Mar 11, 6:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into a definitive purchase agreement under which Quest will acquire Summit Health. Terms of the transaction were not disclosed. Summit Health is a leading provider of on-site prevention and wellness programs primarily for employers.
Quest Diagnostics Shares Down 12.6% Since SmarTrend's Sell Call (DGX)
Comtex SmarTrend(R) - Mon Mar 10, 5:12PM CDT
SmarTrend identified a Downtrend for Quest Diagnostics (NYSE GX) on December 6th, 2013 at $60.25. In approximately 3 months, Quest Diagnostics has returned 12.59% as of today's recent price of $52.66.
Quest Diagnostics Completes Acquisition of Solstas Lab Partners and Raises 2014 Financial Guidance
PR Newswire - Mon Mar 10, 6:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the previously announced acquisition of Solstas Lab Partners Group and its subsidiaries (Solstas), a full-service commercial laboratory company based in Greensboro, North Carolina. The combination of Solstas with Quest Diagnostics will give patients and healthcare providers in the Southeastern United States, where Solstas operates in nine states, including the Carolinas, Virginia, Tennessee, Georgia and Alabama, greater access to innovative and cost-effective diagnostic information services.
Insider Trading Alert - DGX, CELG And HPQ Traded By Insiders
at The Street - Thu Mar 06, 12:30PM CST
Stocks with insider trader activity include DGX, CELG and HPQ
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Nora Therapeutics to Present at 26th Annual ROTH Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton in Laguna Niguel, CA, on Monday, March 10, 2014 at 4:15 p.m. PDT.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Quest Diagnostics Has Returned 12.3% Since SmarTrend Recommendation (DGX)
Comtex SmarTrend(R) - Mon Mar 03, 11:04AM CST
SmarTrend identified a Downtrend for Quest Diagnostics (NYSE GX) on December 6th, 2013 at $60.25. In approximately 3 months, Quest Diagnostics has returned 12.31% as of today's recent price of $52.83.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest Diagnostics, and Illumina
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Medtronic, Inc. (NYSE: MDT), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and Illumina, Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Quest Diagnostics to Buy Summit Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:00PM CDT
Post acquisition, Summit Health's services will complement the health and wellness business of Quest Diagnostics.
Fitch Downgrades Quest Diagnostics' IDR to 'BBB'; Outlook Stable
Business Wire - Wed Mar 12, 9:31AM CDT
Fitch Ratings has downgraded Quest Diagnostics, Inc.'s (Quest) ratings as follows and removed the ratings from Rating Watch Negative:
Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
PR Newswire - Wed Mar 12, 8:24AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $600,000,000 in aggregate principal amount of two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.
After Yesterday's Rally of 2.79% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Mar 11, 5:35PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $53.07 to a high of $54.50. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $53.02 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Watch for Quest Diagnostics to Potentially Pullback After Gaining 2.79% Yesterday
Comtex SmarTrend(R) - Tue Mar 11, 5:34PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $53.07 to a high of $54.50. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $53.02 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Quest Diagnostics Ups View on Solstas Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 4:20PM CDT
With the declaration of the closure of its earlier announced acquisition of Solstas Lab Partners Group and its subsidiaries, Quest Diagnostics also raised its 2014 financial outlook.
Clifford Chance advising Summit Health on its sale to Quest Diagnostics
GlobeNewswire - Tue Mar 11, 4:18PM CDT
Clifford Chance is advising Summit Health, a leading provider of on-site prevention and wellness programs primarily for employers, on its sale to Quest Diagnostics, the world's leading provider of diagnostic information services. The deal is subject to regulatory approvals and other customary closing conditions, and is expected to close in the first half of 2014. Terms of the transaction were not disclosed.
Myriad Stock Tumbles After Court Allows Rival To Sell
at Investor's Business Daily - Tue Mar 11, 10:18AM CDT
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for...
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Quest Diagnostics to Acquire Summit Health
PR Newswire - Tue Mar 11, 6:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into a definitive purchase agreement under which Quest will acquire Summit Health. Terms of the transaction were not disclosed. Summit Health is a leading provider of on-site prevention and wellness programs primarily for employers.
Quest Diagnostics Shares Down 12.6% Since SmarTrend's Sell Call (DGX)
Comtex SmarTrend(R) - Mon Mar 10, 5:12PM CDT
SmarTrend identified a Downtrend for Quest Diagnostics (NYSE
GX) on December 6th, 2013 at $60.25. In approximately 3 months, Quest Diagnostics has returned 12.59% as of today's recent price of $52.66. Quest Diagnostics Completes Acquisition of Solstas Lab Partners and Raises 2014 Financial Guidance
PR Newswire - Mon Mar 10, 6:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the previously announced acquisition of Solstas Lab Partners Group and its subsidiaries (Solstas), a full-service commercial laboratory company based in Greensboro, North Carolina. The combination of Solstas with Quest Diagnostics will give patients and healthcare providers in the Southeastern United States, where Solstas operates in nine states, including the Carolinas, Virginia, Tennessee, Georgia and Alabama, greater access to innovative and cost-effective diagnostic information services.
Insider Trading Alert - DGX, CELG And HPQ Traded By Insiders
at The Street - Thu Mar 06, 12:30PM CST
Stocks with insider trader activity include DGX, CELG and HPQ
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Nora Therapeutics to Present at 26th Annual ROTH Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton in Laguna Niguel, CA, on Monday, March 10, 2014 at 4:15 p.m. PDT.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Quest Diagnostics Has Returned 12.3% Since SmarTrend Recommendation (DGX)
Comtex SmarTrend(R) - Mon Mar 03, 11:04AM CST
SmarTrend identified a Downtrend for Quest Diagnostics (NYSE
GX) on December 6th, 2013 at $60.25. In approximately 3 months, Quest Diagnostics has returned 12.31% as of today's recent price of $52.83. Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
(0)
(0)Quest Diagnostics Inc. (DGX) Stock Research Links
Scroll down for more posts ▼